Clincosm LogoSign in Get a demo

recurrent ovarian cancer

Showing 1 - 25 of 27
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer Trial in Toronto (RP-6306, Carboplatin, Paclitaxel)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Oct 25, 2023

Participation Patterns Among Recurrent Ovarian Cancer Patients

Not yet recruiting
  • Recurrent Ovarian Cancer
    • San Francisco, California
      Power Life Sciences
    Sep 30, 2023

    Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • Pittsburgh, Pennsylvania
      Magee-Womens Research Institute / UPMC Magee Womens Hospital
    Jul 3, 2023

    Recurrent Ovarian Cancer Trial in Shanghai (Fuzuloparib Combination with Bevacizumab)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • Fuzuloparib Combination with Bevacizumab
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Cente
    Apr 14, 2023

    Recurrent Ovarian Cancer Trial (DOXIL, Withaferin A, Ashwagandha)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • (no location specified)
    Jan 27, 2023

    Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer Trial in Australia, Belgium,

    Recruiting
    • Recurrent Ovarian Cancer
    • +2 more
    • Birmingham, Alabama
    • +14 more
    Oct 11, 2022

    Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation, Therapy-Associated Cancer Trial in Netherlands (Letrozole

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • +2 more
    • Letrozole Oral Product
    • +3 more
    • Eindhoven, Brabant, Netherlands
    • +5 more
    Jul 29, 2022

    Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer Trial in Durham, Oklahoma

    Recruiting
    • Recurrent Ovarian Cancer
    • +6 more
    • Durham, North Carolina
    • +2 more
    Jul 26, 2022

    Ovarian Cancer, Endometrial Cancer, Recurrent Ovarian Cancer Trial (BKM120, Nabpaclitaxel)

    Withdrawn
    • Ovarian Cancer
    • +3 more
    • (no location specified)
    Jul 27, 2022

    Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer Trial (Niraparib, Dostarlimab)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • +2 more
    • (no location specified)
    Jul 26, 2022

    Recurrent Ovarian Cancer Trial in Bochum (chemo with doxorubicin and cisplatin)

    Completed
    • Recurrent Ovarian Cancer
    • chemotherapy with doxorubicin and cisplatin
    • Bochum, NRW, Germany
      Ruhr University Bochum
    Jul 7, 2022

    Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Worldwide

    Active, not recruiting
    • Recurrent Ovarian Cancer
    • +2 more
    • Relacorilant, 100mg QD
    • +3 more
    • Birmingham, Alabama
    • +20 more
    Jun 27, 2022

    Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer Trial in Los Angeles (Simvastatin 40mg)

    Recruiting
    • Recurrent Ovarian Cancer
    • Platinum-sensitive Ovarian Cancer
    • Simvastatin 40mg
    • Los Angeles, California
      Cedars Sinai Medical Center
    Apr 21, 2022

    Ovarian Carcinoma, Survival Outcomes, Adverse Events Trial in Beijing (Niraparib plus anlotinib)

    Recruiting
    • Ovarian Carcinoma
    • +8 more
    • Niraparib plus anlotinib
    • Beijing, Beijing, China
      Lei Li
    Apr 5, 2022

    Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma Trial in Columbus (Lenvatinib Mesylate,

    Completed
    • Fallopian Tube Carcinoma
    • +3 more
    • Lenvatinib Mesylate
    • +2 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Apr 5, 2022

    Recurrent Ovarian Cancer Trial in Chengdu (dendritic cell)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • dendritic cell
    • Chengdu, Sichuan, China
      west china second University， SICHUAN University, China
    Feb 25, 2022

    Recurrent Ovarian Cancer Trial in London (Nuc-1031 and Carboplatin)

    Completed
    • Recurrent Ovarian Cancer
    • Nuc-1031 and Carboplatin
    • London, United Kingdom
      Garry Weston Cancer Centre, Hammersmith Hospital
    May 17, 2021

    Recurrent Ovarian Cancer Trial in Worldwide (Bevacizumab, Paclitaxel, Carboplatin)

    Active, not recruiting
    • Recurrent Ovarian Cancer
    • Aix-en-Provence, France
    • +81 more
    Mar 9, 2021

    Platinum-resistant Ovarian Cancer, Recurrent Ovarian Cancer, Palliative Care Trial in Chapel Hill, Durham (Structured Palliative

    Completed
    • Platinum-resistant Ovarian Cancer
    • +2 more
    • Structured Palliative Care
    • Usual Care
    • Chapel Hill, North Carolina
    • +1 more
    May 11, 2020

    Recurrent Ovarian Cancer Trial in Guangzhou (Cryosurgery, NK immunotherapy)

    Completed
    • Recurrent Ovarian Cancer
    • Cryosurgery
    • NK immunotherapy
    • Guangzhou, Guangdong, China
      Fuda cancer institute of Fuda cancer hospital
    Sep 10, 2019

    YONDELIS®+PLD for Treatment of Platinum-sensitive Relapse of

    Completed
    • Recurrent Ovarian Cancer
      • Ebersberg, Bayern, Germany
      • +1 more
      Apr 4, 2018

      Recurrent Ovarian Cancer Trial (Niraparib)

      Approved for marketing
      • Recurrent Ovarian Cancer
      • (no location specified)
      Apr 13, 2017

      Recurrent Ovarian Cancer, Platinum Sensitive Ovarian Cancer Trial in Boston (Carboplatin)

      Terminated
      Has Results
      • Recurrent Ovarian Cancer
      • Platinum Sensitive Ovarian Cancer
      • Boston, Massachusetts
        Massachusetts General Hospital
      Nov 1, 2016

      Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovarian Cancer Trial (Low Dose Fractionated Whole Abdominal Radiation Therapy,

      Withdrawn
      • Ovarian Cancer
      • +3 more
      • Low Dose Fractionated Whole Abdominal Radiation Therapy
      • Docetaxel
      • (no location specified)
      Aug 9, 2016

      Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Recurrent Ovarian Cancer Trial in Minneapolis (Usual Care Educational

      Completed
      • Stage III Ovarian Cancer
      • +3 more
      • Usual Care Educational Website
      • Prototype System
      • Minneapolis, Minnesota
        Masonic Cancer Center, University of Minnesota
      Nov 30, 2015